Search Results
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
an estimated median progression-free survival (PFS) of 28.1 months in the 100–300 mg/day dose range[3]. In January 2026, the global Phase III head-to-head clinical trial comparing rocbrutinib with the third-generation non-covalent BTK inhibitor pirtobrutinib for the treatment of R/R CLL/SLL
More news about: Lupeng Pharmaceutical Ltd
Jun 03, 2026, 18:37 ET SRAD INVESTOR ALERT: Sportradar Group AG Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
crucial for Sportradar's operations; (ii) Sportradar's Know-Your-Customer and compliance processes were not as robust as the defendants had claimed; and (iii) as a result, defendants' statements about Sportradar's business, operations, and prospects lacked a reasonable basis.The Sportradar class
More news about: Robbins Geller Rudman & Dowd LLP
Jun 03, 2026, 18:04 ET Bitmine Immersion Technologies Announces Proposed Series A Perpetual Preferred Stock Offering
business day; and (iii) the arithmetic average of the last reported sale prices per share of Series A Preferred Stock for each trading day of the ten (10) consecutive trading days immediately preceding such business day; provided, however, that, if applicable, the reference in (iii) to ten (10) will be
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 17:49 ET Bitmine Immersion Technologies Announces Proposed Series A Perpetual Preferred Stock Offering
business day; and (iii) the arithmetic average of the last reported sale prices per share of Series A Preferred Stock for each trading day of the ten (10) consecutive trading days immediately preceding such business day; provided, however, that, if applicable, the reference in (iii) to ten (10) will be
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 17:13 ET Bitmine Immersion Technologies (BMNR) annuncia che le sue partecipazioni in ETH raggiungono i 5,42 milioni di token e che le partecipazioni totali in criptovalute e liquidità ammontano a 11,6 miliardi di dollari
continua a essere sostenuta da un gruppo di investitori istituzionali di prim'ordine tra cui ARK di Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e l'investitore privato Thomas "Tom" Lee a sostegno dell'obiettivo di Bitmine di acquisire il 5% di ETH
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 17:05 ET BitMine Immersion Technologies (BMNR) anuncia que suas participações em ETH somam 5,42 milhões de tokens e que o total em criptomoedas e caixa é de US$ 11,6 bilhões
Bitmine continua apoiada por um grupo de investidores institucionais de destaque, incluindo Cathie Wood da ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e o investidor individual Thomas "Tom" Lee, para apoiar a meta da Bitmine de adquirir 5% do ETH
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 17:00 ET Bank of America and FIFA partner with Vet Tix to Offer Thousands of Free FIFA World Cup 2026™ Tickets to Veterans, Current Military and First Responders
the veteran, military and first responder communities we proudly serve," said Vet Tix Founder, CEO, and U.S. Navy veteran Michael A. Focareto III. "The opportunity for our members and their families to experience the energy, pride, and global celebration surrounding the World Cup in all 11
More news about: Bank of America Corporation
Jun 03, 2026, 16:56 ET Bitmine Immersion Technologies (BMNR) anuncia que sus tenencias de ETH alcanzan los 5,42 millones de tokens y sus tenencias totales en criptomonedas y efectivo ascienden a 11.600 millones de dólares
con el apoyo de un grupo selecto de inversionistas institucionales, entre los que se incluyen Cathie Wood de ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital y el inversionista particular Thomas "Tom" Lee, para respaldar el objetivo de Bitmine de adquirir el 5 % de ETH
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 16:54 ET Bitmine Immersion Technologies (BMNR) 宣佈其以太幣 (ETH) 持有量達 542 萬枚，加密資產及現金總持有額達 116 億美元
為美國第 225 大最活躍交易股票，每日平均成交額達 6.28 億美元（4 日平均）Bitmine 持續獲得頂級機構投資者支持，包括 ARK 的 Cathie Wood、MOZAYYX、Founders Fund、Bill Miller III、Pantera、Kraken、DCG、Galaxy Digital 以及個人投資者 Thomas "Tom" Lee，攜手支持 Bitmine 收購 5% 以太幣的目標康涅狄格州諾沃克2026年6月4日
More news about: Bitmine Immersion Technologies, Inc.
Jun 03, 2026, 16:15 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are in clinical or preclinical development and the risk of failure is high and can unexpectedly
More news about: Nektar Therapeutics
Jun 03, 2026, 16:10 ET YY Group (NASDAQ: YYGH) Advances AI Training Data Strategy with Launch of Training Lab and Pilot Robotics Deployments in Singapore
the hospitality market across Southeast Asia, Hong Kong, and other markets in which the Company operates, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, (vi) our ability to successfully
More news about: YY Group Holding Limited
Jun 03, 2026, 16:05 ET Petco Reports First Quarter 2026 Results
from multi-channel retailers, mass and grocery retailers, and e-Commerce providers); (ii) reduced consumer demand for our products and/or services; (iii) our reliance on key vendors; (iv) our ability to attract and retain qualified employees; (v) risks arising from statutory, regulatory and/or legal developments;
More news about: Petco - Investor Relations
Jun 03, 2026, 13:35 ET EVROPSKÁ KOMISE SCHVÁLILA PŘÍPRAVEK IMDYLLTRA® OD SPOLEČNOSTI AMGEN K LÉČBĚ EXTENZIVNÍHO STADIA MALOBUNĚČNÉHO KARCINOMU PLIC
časnějších stadiích SCLC, tak v časnějších liniích léčby. O studii fáze III DeLLphi-304DeLLphi-304 je globální randomizovaná, kontrolovaná, otevřená klinická studie fáze III, která hodnotí účinnost a bezpečnost přípravku IMDYLLTRA jako léčby pro pacienty s SCLC,
More news about: Amgen
Jun 03, 2026, 12:04 ET RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for
More news about: RedHill Biopharma Ltd.
Jun 03, 2026, 10:57 ET Ascendion Named an AI Leader by ISG for Integrated Platform and Application Services
III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises,
More news about: Ascendion
Jun 03, 2026, 10:47 ET The $1 Billion Bet to Take Fusion Public
Vancouver-based company, led by CEO Greg Twinney, is preparing to go public through a business combination with Spring Valley Acquisition Corp. III (NASDAQ: SVAC), a transaction targeted to close in mid-2026, after which the combined company is expected to trade under the ticker "GFUZ."Founded
More news about: Equity Insider
Jun 03, 2026, 10:34 ET Ascendion Named an AI Leader by ISG for Integrated Platform and Application Services
III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises,
More news about: Ascendion
Jun 03, 2026, 10:21 ET KOMISJA EUROPEJSA ZATWIERDZA PREPARAT IMDYLLTRA® FIRMY AMGEN DO LECZENIA DROBNOKOMÓRKOWEGO RAKA PŁUCA W POSTACI ROZSIANEJ
SCLC oraz we wcześniejszych rzutach leczenia.Badanie kliniczne fazy III DeLLphi-304DeLLphi-304 to globalne, randomizowane, kontrolowane, otwarte badanie fazy III oceniające skuteczność i bezpieczeństwo IMDYLLTRY u pacjentów z SCLC, u których doszło do progresji
More news about: Amgen
Jun 03, 2026, 10:03 ET Advanced Green Holdings Engages Anglo-Suisse Capital in Connection With US$1 Billion Boco Tora Development in Belize
and discipline we want behind a project of this scale and we share a commitment to building something lasting for Belize."Herb Gray Dogan III, Chief Executive Officer of Advanced Green Holdings."Belize is fast becoming an international destination and Boco Tora is
More news about: Boco Tora
Jun 03, 2026, 10:01 ET T-cell Malignancies Market to Accelerate Substantially at a CAGR of 5.2% During the Forecast Period (2026-2036) | DelveInsight
2025. These results provide the foundation for the ongoing registration Phase III trial in r/r PTCL.In November 2025, Innate announced that the US FDA had completed its review of the confirmatory Phase III protocol for lacutamab in CTCL, with no further comments, clearing the trial to
More news about: DelveInsight Business Research, LLP
Jun 03, 2026, 09:32 ET ThroughPut.AI Now Available on SBIR Aisle of CDAO's Tradewinds Solutions Marketplace
integrity or process intervention. These capabilities already support U.S. Air Force aircraft availability and parts readiness through multiple SBIR Phase III awards, as well as the US Army Reserve for Mobilization Readiness."The Department of War needs an Easy Button to impact Aircraft & Equipment
More news about: ThroughPut Inc.
Jun 03, 2026, 09:00 ET AOPO Announces 2026-2027 Board Leadership
Welcomes New Board LeadersAOPO also welcomes newly elected leaders to the Board of Directors for the 2026–2027 term.Harry Wilkins III, MD, President & CEO of Gift of Hope Organ & Tissue Donor Network, joins the executive leadership team as President-Elect. A former trauma surgeon
More news about: Association of Organ Procurement Organizations
Jun 03, 2026, 09:00 ET IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline
value in a single trading session, falling from $2.76 to $0.48 per share, after the Company disclosed on March 13, 2026 that its pivotal TACTI-004 Phase III trial was being discontinued for futility.What They Allegedly Knew Before Shareholders DidThe action contends that
More news about: Levi & Korsinsky, LLP
Jun 03, 2026, 08:00 ET CRC CEO Tom Zoda, Ph.D., Chairs ASCP 2026 Panel on Preventable Failure Risk in CNS Clinical Trials
https://ascpp.org/meeting-hub/.About Cognitive Research CorporationCognitive Research Corporation (CRC) is a neuroscience-specialty CRO supporting Phase I-III clinical trials across neurology, psychiatry, and analgesia. With 20 years of exclusive focus on CNS research, CRC combines scientific expertise with
More news about: Cognitive Research Corporation
Jun 03, 2026, 08:00 ET Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
imaging (WSI), digital slide visualization platforms, and advanced AI algorithms.The collaboration will leverage the BOND RX research stainer, BOND-III clinical stainer, Aperio GT 450 scanner, and the Aperio HALO AP image management system from Leica Biosystems to support rapid development and global
More news about: Leica Biosystems